Catalysts · GILD · CIK 882095 · page 2 of 2

GILD catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on GILD PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
April 2030Month disclosedsacituzumab govitecan-hziy (IMMU-132)GILDPrimary completionMetastatic Urothelial CancerScheduledClinicalTrials.gov
Apr to Jul 2030Quarter disclosedsacituzumab govitecan-hziy (IMMU-132)GILDTopline readoutMetastatic Urothelial CancerScheduledClinicalTrials.gov
July 2030Month disclosedYeztugo® (lenacapavir)GILDPrimary completionHIV-1-infectionScheduledClinicalTrials.gov
Jul to Oct 2030Quarter disclosedYeztugo® (lenacapavir)GILDTopline readoutHIV-1-infectionScheduledClinicalTrials.gov
August 2030Month disclosedLivdelzi® (seladelpar)GILDPrimary completionPrimary Biliary CholangitisScheduledClinicalTrials.gov
Aug to Nov 2030Quarter disclosedLivdelzi® (seladelpar)GILDTopline readoutPrimary Biliary CholangitisScheduledClinicalTrials.gov
October 2030Month disclosedYescarta (axicabtagene ciloleucel)GILDPrimary completionRelapsed/Refractory Follicular LymphomaScheduledClinicalTrials.gov
Oct 2030 to Jan 2031Quarter disclosedYescarta (axicabtagene ciloleucel)GILDTopline readoutRelapsed/Refractory Follicular LymphomaScheduledClinicalTrials.gov
October 2030Month disclosedYeztugo® (lenacapavir)GILDPrimary completionHIV-1-infectionScheduledClinicalTrials.gov
Oct 2030 to Jan 2031Quarter disclosedYeztugo® (lenacapavir)GILDTopline readoutHIV-1-infectionScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
October 27, 2025Yeztugo® (lenacapavir)GILDPrimary completionHIV-1-infectionCompletedClinicalTrials.gov
September 29, 2025Yeztugo® (lenacapavir)GILDPrimary completionHIV-1-infectionCompletedClinicalTrials.gov
August 7, 2025—GILDEarnings—CompletedSEC 8-K Exhibit 99.1
July 30, 2025Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
July 4, 2025sacituzumab govitecan-hziy (IMMU-132)GILDPrimary completionLocally Advanced or Metastatic Unresectable Urothelial CancerCompletedClinicalTrials.gov
2H 2025Half-year disclosedYeztugo® (lenacapavir)GILDTrial start—ScheduledSEC 8-K Exhibit 99.1
June 20, 2025Descovy (emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
June 20, 2025Tybost (cobicistat)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
June 19, 2025Yeztugo® (lenacapavir)GILDPDUFA date—ApprovedSEC 8-K Exhibit 99.1
June 18, 2025Yeztugo (lenacapavir; lenacapavir sodium)GILDFDA approval—ApprovedopenFDA Drugs@FDA
June 18, 2025Yeztugo® (lenacapavir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
June 17, 2025fludarabineGILDPrimary completionRelapsed/Refractory Mantle Cell LymphomaCompletedClinicalTrials.gov
June 13, 2025Tybost (cobicistat)GILDPrimary completionAcquired Immune Deficiency Syndrome (AIDS); HIV InfectionsCompletedClinicalTrials.gov
May 8, 2025obeldesivir (GS-5245)GILDPrimary completionRSV InfectionWithdrawnClinicalTrials.gov
April 24, 2025—GILDEarnings—CompletedSEC 8-K Exhibit 99.1
April 24, 2025Yeztugo® (lenacapavir)GILDNDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
February 19, 2025Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 11, 2025—GILDEarnings—CompletedSEC 8-K Exhibit 99.1
November 25, 2024Yeztugo® (lenacapavir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
August 14, 2024Livdelzi® (seladelpar)GILDFDA approvalTo treat primary biliary cholangitis (PBC)ApprovedFDA Novel Drug Approvals
April 24, 2024Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
March 27, 2024Vemlidy (tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 28, 2024Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 23, 2024Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
July 13, 2023Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
December 22, 2022Yeztugo® (lenacapavir)GILDFDA approval—ApprovedFDA Novel Drug Approvals
October 17, 2022Vemlidy (tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
October 14, 2022Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
Oct 2022Month disclosedHepcludex® (bulevirtide)GILDComplete Response Letterwith hepatitis delta virus infectionCRL issuedSEC Form 10-Q
April 27, 2022Epclusa (sofosbuvir; velpatasvir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
April 25, 2022Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 28, 2022Yeztugo® (lenacapavir)GILDComplete Response Letter—CRL issuedFDA Complete Response Letters
January 21, 2022Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
January 7, 2022Descovy (emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
January 7, 2022Genvoya (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
October 7, 2021Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
June 10, 2021Epclusa (sofosbuvir; velpatasvir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
June 10, 2021Epclusa (sofosbuvir; velpatasvir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
February 24, 2021Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 5, 2021Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
October 22, 2020Veklury (remdesivir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
August 18, 2020Vemlidy (tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
July 14, 2020Epclusa (sofosbuvir; velpatasvir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
March 19, 2020Epclusa (sofosbuvir; velpatasvir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 4, 2020Vemlidy (tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
August 28, 2019Sovaldi® (sofosbuvir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
August 28, 2019Harvoni (ledipasvir; sofosbuvir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
February 7, 2018Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDFDA approval—ApprovedopenFDA Drugs@FDA
July 18, 2017Vosevi (sofosbuvir; velpatasvir; voxilaprevir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
November 10, 2016Vemlidy (tenofovir alafenamide fumarate)GILDFDA approval—ApprovedopenFDA Drugs@FDA
June 28, 2016Epclusa (sofosbuvir; velpatasvir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
April 4, 2016Descovy (emtricitabine; tenofovir alafenamide fumarate)GILDFDA approval—ApprovedopenFDA Drugs@FDA
March 1, 2016Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate)GILDFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from GILD’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.